Grace Therapeutics Inc. has amended its compensation agreements for key executives, including CEO Prashant Kohli and Principal Financial Officer Robert J. DelAversano. Under the new terms, if an executive is terminated without cause outside of a change in control, they will receive accrued salary and benefits, as well as a continuation of base salary and COBRA premium payments for six months, or twelve months for the CEO. In the event of a termination without cause or resignation for good reason within twelve months following a change in control, executives are entitled to a lump-sum payment equal to six months of base salary and target bonus, or eighteen months for the CEO, along with corresponding COBRA premium coverage. Additionally, all unvested equity awards will fully vest in connection with such terminations related to a change in control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-000995), on January 12, 2026, and is solely responsible for the information contained therein.